• DUSS · OTC
  • EMXC · OTC
  • TYTN · OTC
  • TDGI · OTC
  • Tagged celerate RX

    TVGoods, Inc. Announces Spanish Media Campaign for Wound Management’s CellerateRX(R) (WNDM.QB)

    Posted on September 23, 2011 by Dana Salvo


    TVGoods Inc. (“TVGoods”), a direct response marketing company and wholly owned subsidiary of H & H Imports, Inc. (PINKSHEETS: HNHI) (OTCQB: HNHI), has announced the launch of the media campaign for CellerateRX®. CellerateRX® (OTCQB: WNDM) is a revolutionary bovine-based collagen that is designed to heal wounds like no other product on the market.

    TVGoods produced a short form infomercial which was dubbed in Spanish for domestic distribution. The infomercial spot is set to roll out on 50 television properties in 36 states across the U.S. The spot is geared toward the Hispanic consumer market and is aimed to drive retail sales to big box and other national and local retailers.

    TVGoods’ initial agreement to produce an infomercial for CellerateRX® was announced on March 1, 2011. TVGoods has an exclusive relationship with Marketing Media Enterprises, LLC to distribute CellerateRX® via CABAN BROADCASTING, LLC. CABAN BROADCASTING, LLC is a boutique network services firm that focuses on matching networks with carriers and advertisers that want to reach the U.S. markets from around the globe.

    Steve Rogai, CEO of TVGoods, stated, “We believe this is a tremendous opportunity for TVGoods. We are excited to have secured media placement for a product with such a promising future in the large Spanish market.”

    Carlos Caban, CEO and President of CABAN BROADCASTING LLC, an exclusive partner of Marketing Media Enterprises, LLC, stated, “We are happy working on this project with MME, LLC and TVGoods. Our television networks in the U.S.A. are ready for the relationship.”

    Laura Hayes-Reeves, President of Marketing Media Enterprises, LLC, stated, “We are delighted and look forward to success with what I believe is a game changing product. We stand poised to expand the relationship with Caban Broadcasting and the Spanish market.”

    About The Company:
    H & H Imports, Inc. is the parent company of TV Goods, Inc. TV Goods, Inc. is a direct response marketing company. We identify, develop and market consumer products for global distribution. TV Goods was established by Kevin Harrington, a pioneer of direct response television. For more information, go to www.TVGoodsInc.com.

    TheStockWizards.net Weekly Newsletter Reviews SAVW, SNGX, MNAP, OPMG, and LBSR as Stocks of Interest

    Posted on July 9, 2011 by Dana Salvo

    SavWatt USA, Inc. (SAVW.OTCBB)

    July 9, 2011 West Palm Beach.FL–TheStockwizards.net penny stock trading system analyzes the most notable explosive OTC, OTCBB, NASDAQ Micro Cap Penny Stocks such as SAVW with huge volume and positive change.

    The TSW Weekly Top 10 watch list looks for OTC small cap penny stocks that have some kind of technical analysis set up in the charts like SAVW. TSW looks for moving average breakouts, chart pattern breakouts, bottom reversals, volume accumulation and more.

    OTC Small-Cap Penny Stocks showing potential momentum, volume accumulation for the coming week include SAVW, SNGX, MNAP, PCFG, OPMG, LBSR, KNKT, EGOH, ADHC and WNDM.

    1-SavWatt USA, Inc. (SAVW.OTCQB) -.0039

    SAVW is getting ready to breakout above its 100-day moving average. A weekly close above this key moving average could set the stock up for an explosive move to the upside. First level of resistance will be the psychological .005 level in the short-term.

    SAVW, SNGX, MNAP, OPMG, LBSR SavWatt is leading the LED lighting revolution and setting the stage to obsolete the incandescent light bulb through the use of energy-efficient, environmentally friendly LED lighting. SavWatt is a market-leading innovator of LED lighting. SavWatt’s product families include LED fixtures, bulbs, Street Lights and Parking Lights. For additional product and company information, please refer to www.savwatt.com. To hear Recorder updates on the company Text SAVW to 46800.

    2- Soligenix, Inc. (SNGX.OTCQB) - .30

    TSW subscribers made a killing in 2009 with the biotech pharmaceutical craze. Could the last six months of 2011 bring us more winners in the biotech pharmaceutical sectors? TSW is adding SNGX to its Biotech watch list.

    Coming out of a nice consolidation pattern SNGX exploded to close the week at a new 52-week high. Strong support .25 first resistance is .38-.40. There could be forward-looking events coming up in the fourth quarter of the year so the stock could possibly continue to move higher from here.

    Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development of products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, as well as biodefense vaccines and therapeutics.

    3- Manas Petroleum Corp. (MNAP.OTCQB) -.40

    Traders and investors felt MNAP was oversold from these levels and bid the stock higher. MNAP had a weekly close above the 50-day moving average. This was an extremely bullish technical event.

    Another weekly close above this key moving average will get the attention of technical traders and could spark another round of momentum buying. With oil closing in on $100 a barrel again, MNAP looks attractive at these levels.

    Manas Petroleum is an international oil and gas company with primary focus on exploration and development in South-Eastern Europe, Central Asia and Mongolia. In Albania, Manas participates in a 1.7 million acre exploration project through its equity interest in Petromanas Energy Inc., a Canadian public company.
    Read the rest of this entry »

    Special Biotech Report on Wound Management Technologies (OTCBB:WNDM)

    Posted on March 2, 2011 by Dana Salvo

    The Stock Wizards Featured Profile

    TV Website for CellerateRX (Brought to you by TV Goods)


    Wound Management Technologies, Inc

    Current Price - 0.615 Cents

    www.WmgTech.com WNDM

    Wound Management Technologies, Inc. (WNDM) is a rapidly growing provider of advanced biotechnology products. The company’s unique, patented CellerateRX® products address the very large and growing advanced wound care markets. The U.S. market in 2007 was $3.0B and is projected to double by 2013 (source BCC research).

    With an amazing product like CellerateRX® and a market cap of only approx. 23 million, The Stock Wizards is very surprised to see WNDM trading down at these levels.

    Here is a list of some very impressive features of CellerateRX®:

    *No prescription required.

    *Reduces pain.

    *Cost effective.

    *Reimbursed by Medicare in most States.

    *Cleared by the FDA as a medical device for use on all acute and chronic wounds except for 3rd degree burns.

    *Available in powder and gel.

    *Biocompatible, biodegradable.

    *Easy to use - prepare the wound bed, apply product, cover it up.

    *Used to treat diabetic wounds. The diabetic and long term care markets are a major focus due to the prevalence of diabetic and pressure ulcers.

    “The clinical results we have observed have validated the science beyond the product. I would highly recommend CellerateRX® to any conscientious wound care provider”Desmond P Bell, Jr. DPM, President & Co-Founder, Save a Leg, Safe a Life Foundation.

    Core Revenue Stream: Wound Care Innovations, LLC (WCI)
    Wound Care Innovations is a wholly owned subsidiary of WNDM and brings a unique and dynamic mix of expertise, products, procedures and service to the wound care arena. WCI was formed with the sole purpose of bringing CellerateRX® and activated collagen-based products to the $3B US wound care market. Since then, WCI has expanded marketing internationally.

    Evidence-based Clinical Studies
    CellerateRX® has current and on-going evidenced-based studies and other clinical peer reviewed publications. These can be found on the CellerateRX website.

    Sales & Marketing Channel Expansion
    Having completed evidence-based studies, the company developed its sales channel plan and engaged sales & marketing executives in April 2010.

    Strategic Biotechnology Acquisitions, Products
    In the fall of 2009 WMND acquired a patent for resorbable bone wax and bone void filler products in a subsidiary: Resorbable Orthopedic Products, LLC. The worldwide bio materials market for these types of products is over $1.4 Billion. WNDM anticipates our new products will be cleared by the FDA and ready for marketing in the 1H 2011.

    eHealth Technology Acquisition
    In February 2010, WNDM acquired secure data and messaging provider Secure eHealth, LLC. Secure eHealth has a complete suite of scalable products for secure intelligent healthcare communication, collaboration, storage and transport.

    Market Cap: approx. $23.15M (03/01/11)
    Recent Price: $0.615 (03/01/11)
    Shares Outstanding: 37,661,225 (3Q 2010)
    Estimated Float: 3.3M
    Fiscal Year: December 31

    2011 Projections
    Revenue: $6 M
    Net Income: $1.4 M


    Discloser, Disclaimers: http://thestockwizards.net/about/disclaimer/

    Read the rest of this entry »